PD-1 Regulates the Growth of Human Mastocytosis Cells
Authors:
- Tatsuki R. KataokaTKTatsuki R. Kataoka
- Masakazu FujimotoMFMasakazu Fujimoto
- Koki MoriyoshiKMKoki Moriyoshi
- Itsuko KoyanagiIKItsuko Koyanagi
- Chiyuki UeshimaCUChiyuki Ueshima
- Fumihiko KonoFKFumihiko Kono
- Tatsuaki TsuruyamaTTTatsuaki Tsuruyama
- Yoshimichi OkayamaYoshimichi Okayama
- Chisei RaCRChisei Ra
- Hironori HagaHHHironori Haga
Open Access
- 1 January 2013
- journal article
- Published by Japanese Society of Allergology in Allergology International
- Vol. 62 (1) , 99-104
Abstract
BackgroundProgrammed death-1 (PD-1) is a marker for human neoplastic T cells. Here, we evaluated whether or not PD-1 was also a marker for human mastocytosis, and explored the role of PD-1 in human mastocytosis cells.MethodsImmunohistochemical analysis was used to evaluate the expression of PD-1 in clinical samples of human cutaneous mastocytosis. The expression of PD-1 in human mastocytosis cell lines was checked by RT- PCR, western blotting and flow cytometry. We stimulated human mastocytosis cell lines (LAD2 and HMC1.2) with recombinant ligand for PD-1, PD-L1 (rPD-L1), and tested the proliferative activity and the status of signal molecules by Cell Counting Kit-8 and ELISA, respectively.ResultsTen of 30 human cutaneous mastocytosis cases (33.3%) expressed PD-1 protein. We also found that a human mastocytosis line LAD2 cells expressed PD-1 protein on their surfaces. The administration with rPD-L1 suppressed the stem cell factor-dependent growth of the LAD2 cells. And, rPD-L1 activated SHP-1 and SHP-2 simultaneously, and decreased the phosphorylation of AKT, in LAD2 cells. In contrast, we could not detect the expression of PD-1, and the significant effect of rPD-L1 on the mutated KIT-driven growth of HMC1.2 cells.ConclusionsPD-1 could be a marker for human cutaneous mastocytosis and regulate the growth of human PD-1-positive mastocytosis cellsKeywords
This publication has 25 references indexed in Scilit:
- CD84 Negatively Regulates IgE High-Affinity Receptor Signaling in Human Mast CellsThe Journal of Immunology, 2011
- Anti–ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti–PD-1 or anti-CD137 mAb therapyProceedings of the National Academy of Sciences, 2011
- The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti–PD-1 antibodyBlood, 2010
- CD72 Negatively Regulates KIT-Mediated Responses in Human Mast CellsThe Journal of Immunology, 2010
- PD-L1 regulates the development, maintenance, and function of induced regulatory T cellsJournal of Experimental Medicine, 2009
- Mast cells and mastocytosisBlood, 2008
- Pharmacological targeting of the KIT growth factor receptor: a therapeutic consideration for mast cell disordersBritish Journal of Pharmacology, 2008
- Nuclear Expression of STAT5 in Intraductal Papillary Mucinous Neoplasms of the PancreasInternational Journal of Surgical Pathology, 2007
- Programmed Death-1 (PD-1) is a Marker of Germinal Center-associated T Cells and Angioimmunoblastic T-Cell LymphomaAmerican Journal of Surgical Pathology, 2006
- Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product.Journal of Clinical Investigation, 1993